Background-Current organ allocation algorithms direct hearts to the sickest recipients to mitigate death while waiting. This may result in lower post-transplant (Tx) survival for high-risk candidates mandating close examination to determine the appropriateness of different technologies as a bridge to Tx. Methods and Results-We analyzed all patients (<18 years old) from the Pediatric Heart Transplant Study (PHTS) database listed for heart Tx (1993-2013) to determine the effect of extracorporeal membrane oxygenation (ECMO) support at the time of listing and the time of Tx on waitlist mortality and post-Tx outcomes. Eight percent of patients were listed on ECMO, and within 12 months, 49% had undergone Tx, 35% were deceased, and 16% were alive waiting. Survival at 12 months after listing (censored at Tx) was worse in patients on ECMO at listing (50%) compared with ventricular assist device at listing (76%) or not on ECMO or ventricular assist device at listing (76%; P<0.0001). Two hundred three (5%) patients underwent Tx from ECMO; 135 (67%) had been on ECMO since listing, and 67 (33%) had deteriorated to ECMO support while waiting. Survival after Tx was worse in patients who underwent Tx from ECMO (3 years: 64%) versus on ventricular assist device at Tx (3 years: 84%) or not on ECMO/ventricular assist device at Tx (3 years: 85%; P<0.0001). Patients transplanted from ECMO at age <1 year had the worst survival. Conclusions-Pediatric patients requiring ECMO support before heart Tx have poor outcomes. Prioritization of donor hearts to children waitlisted on ECMO warrants careful consideration because of ECMO's high pre-and post-Tx mortality. (Circ Heart Fail. 2015;8:960-969.
M echanical circulatory support for the failing heart has been extensively used as a bridge to heart transplantation in both adult and pediatric populations. [1] [2] [3] [4] [5] Extracorporeal membrane oxygenation (ECMO) has long been the primary means of mechanical support for pediatric patients with end-stage cardiac failure. However, ECMO is associated with many known complications, including thromboembolic events, bleeding, immobilization, infection, end-organ dysfunction, and risk of neurological impairment, thus making the need for alternative methods of pediatric mechanical circulatory support necessary. 6 Bridge to transplant with ECMO support is associated with high waitlist mortality and a poor survival to hospital discharge. [5] [6] [7] [8] [9] [10] [11] [12] Current organ allocation algorithms have been developed to direct hearts to the sickest recipients to mitigate death while waiting. Such a strategy may result in suboptimal post-transplant survival for certain high-risk candidates, including those on ECMO. In the evolving era of mechanical support, outcomes must be closely examined to determine the appropriateness of existing allocation algorithms, criteria for candidacy for heart transplantation, and the effect of different technologies as a bridge to transplant. 11 The purpose of this study was to describe and analyze the outcomes for pediatric patients waitlisted on or transplanted from ECMO support in comparison with those without ECMO support and to attempt to define risk factors associated with worse outcomes so as to gain an understanding of when it might be futile to perform a transplant on candidates on ECMO. of children <18 years of age listed for primary transplantation from 35 pediatric heart transplantation centers in North America and the United Kingdom (Data Supplement). PHTS data collection and management have been described previously. 13 Institutional Review Board approval was obtained at the transplant centers and the data analysis and coordinating center.
All patients who were listed for heart transplantation between January 1, 1993 and December 31, 2013 with a record of ECMO as a bridge to transplant were included. Comparisons were made to all patients in the registry who were not bridged to transplantation from ECMO support. Data collected included demographics, United Network for Organ Sharing status at listing, support at listing (intravenous inotropes, ventilator, prostaglandin, ECMO, and ventricular assist device [VAD]), timing of ECMO support or VAD placement post listing, hemodynamics at listing and any during follow-up, human leukocyte antigen sensitization, surgical palliation while waiting, clinical condition at listing, death while waiting, delisting, indications for removal from waitlist, transplant, United Network for Organ Sharing status at transplant, support at the time of transplant (eg, ECMO and VAD), cardiopulmonary bypass time, ischemic time, donor characteristics, hospital stay, days in intensive care unit, date of most recent follow-up, incidence of primary graft failure, rejection, infection, malignancies, allograft vasculopathy, death post-transplant, and cause of death.
Statistical Methods
Standard Kaplan-Meier and parametric analyses were used for survival analysis. Competing-outcome methods were used to analyze outcome after listing. 14 Multivariate analysis in the hazard-function domain was used to identify risk factors for death while waiting, death after transplant, and overall survival after listing, including death while waiting and death after transplant using a step-wise selection technique. 15 Candidate variables entered into the multivariable risk factor analysis for death after listing (censored at transplant) included demographics at listing, blood type, listing status, underlying cardiac diagnosis, surgical history, other clinical diagnoses/comorbidities, and hemodynamics. Variables entered into the multivariable risk factor analysis for death after transplant included demographics at transplant, status at transplant, underlying cardiac diagnosis, surgical history at listing, other clinical diagnoses/comorbidities, hemodynamics at transplant, donor variables (demographics, blood type, and medical history), and donor-recipient mismatch variables (race, sex, age, blood group, and body surface area ratio).
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the article as written.
Results

Patient Population
Patient demographics and clinical characteristics at listing and transplant are summarized in Table 1 . Of the 5360 patients listed over this time period, there were 453 (8%) patients listed on ECMO support at a median age of 0.56 (0.05-2.69) years, who were significantly younger, smaller, sicker, and more likely to have renal insufficiency than those not supported on ECMO at listing. Fifty-eight percent had a diagnosis of congenital heart disease. Of the 3826 transplanted patients, 203 (5%) were on ECMO support at a median age of 0.80 (0.22-4.37) years, who were similarly younger, smaller, sicker, and more likely to have renal insufficiency than those not on ECMO at transplant. Patients on ECMO support at the time of transplant had a significantly shorter waitlist duration (24 versus 93 days; P<0.0001). One hundred thirteen patients (56%) had a diagnosis of congenital heart disease. Table 2 gives the frequencies at listing by age at listing of patients on ECMO support (n=453), VAD (n=198), and neither ECMO nor VAD (n=4709). Age at the time of listing on ECMO support was <1 month (n=128; 28%), 1 month to 1 year (n=141; 31%), 1 to 5 years (n=100; 22%), 5 to 10 years (n=45; 10%), and >10 years (n=39; 9%). Of the total number of listed patients, 668 transitioned to VAD support while listed (12%) but were analyzed according to their support at the time of listing or at the time of transplant as appropriate (73 of these patients were on ECMO support and transitioned to VAD).
Overall Survival
Overall survival post listing and post transplant for patients waitlisted on ECMO is depicted in Figure 1A (including deaths and follow-up after transplant) with a significantly decreased overall survival for this group (P<0.0001).
ECMO at Listing, Death While Waiting
Patients waitlisted on ECMO support had significantly decreased survival post-listing (censored at transplant) compared with patients on VAD support or no mechanical support (P<0.0001; Figure 1B ). Figure 2 shows the competing outcomes after listing for ECMO, VAD, and neither ECMO nor VAD. Overall waitlist mortality by 1 and 6 months post listing for any pediatric patient waitlisted on ECMO was 28% and 35%, respectively, in contrast to the remarkably low waitlist mortality for VAD patients of 6% and 12%, respectively. By 12 months post listing, 49% of patients listed on ECMO support were transplanted compared with 79% of VAD patients and 72% of all others ( Figure 2 ). Causes of death post listing for patients on ECMO are summarized in Table 3 .
Effect of Age on Post-Listing Survival
Younger age at listing was significantly associated with waitlist mortality, with the smallest of infants (<1 month) having the highest mortality, even without a need for mechanical support ( Figure 3A ). This was worsened significantly by the need for ECMO support at the time of listing and was seen in all age groups ( Figure 3B ). The youngest infants continued to have the worst outcomes with a waitlist mortality of 67% by 3 months post listing if they were on ECMO support at the time of listing (P<0.0001).
Effect of Other Risk Factors on Post-Listing Survival
The PHTS database did not begin to accurately capture duration of mechanical support until January 1, 2005. Figure 4 illustrates survival after listing by duration of time on ECMO before listing, which did not seem to have a significant effect on survival post-listing overall (P=0.66). In univariate analysis, renal insufficiency did not have a significant effect on overall survival (P=0.12), although it is notable that a significant proportion of patients on ECMO had renal insufficiency ( Table 1 ).
Effect of Underlying Cardiac Diagnosis on Outcomes Post-Listing
There was a significant difference in survival based on underlying cause ( Figure 5A ), with patients with myocarditis having the best overall survival post-listing, followed by cardiomyopathy and subsequently a diagnosis of congenital heart disease (P=0.0008). This being said, of the 59 patients with myocarditis, only 10 were removed from the list for recovery. Only 7 of the 25 transplanted patients with myocarditis on ECMO at listing were not on ECMO at the time of transplant.
ECMO at Transplant, Death Post-Transplant
Patients transplanted while on ECMO support had significantly decreased survival post-transplant compared with patients on VAD support or no mechanical support (P<0.0001; Figure 1C ). Patients with myocarditis had the worst outcomes when transplanted from ECMO support, followed by congenital heart disease, with patients with cardiomyopathy having the best post-transplant survival (P=0.0005; Figure 5B ). Infants <1 year of age had significantly worse post-transplant survival when transplanted from ECMO (P<0.0001; Figure 6 ). Table 4 summarizes the scenarios for mechanical support as a bridge to transplantation in the transplant recipients. Figure 7 illustrates the survival for each of the 4 possible ECMO combinations (there were 46 patients listed on ECMO but were weaned and removed from listing because they were considered too well. These patients were censored at the time of removal from listing.) Notably, if a patient was on ECMO at listing but weaned off before transplantation or converted to VAD, their outcome was just as good as not being on ECMO at the time of listing or transplantation. ECMO at the time of transplantation (with or without ECMO support at the time of listing) was significantly associated with worse outcomes (P<0.0001). Unadjusted hazard ratio for death while waiting for patients waitlisted on ECMO censored at transplant was 2.46 (P<0.0001). After adjustment, the hazard ratio remained significant at 1.73 (P=0.03). Table 5 summarizes the risk factors for death on the waitlist, censored at transplant, from the multivariable hazard analysis.
ECMO at Listing and at Transplant and Effect on Overall Survival
On multivariate analysis, overall survival after transplantation for patients on ECMO at the time of transplantation was not affected by age, ischemic time, or duration of time on ECMO. However, lower weight (risk ratio, 1.37 for a 10-kg decrease in weight; P=0.04), higher serum creatinine (risk ratio, 2.36 for a 1-unit increase in creatinine; P=0.007), and an underlying diagnosis of congenital heart disease or myocarditis (risk ratio, 2.68; P=0.009) were risk factors in the early phase ( Table 6 ).
Discussion
We present a large multicentre experience with ECMO as a bridge to transplant in the pediatric population. Pediatric patients requiring ECMO support before heart transplant have poor outcomes, and serious consideration needs to be given to the candidacy of these patients. Prioritization of donor hearts to children waitlisted on ECMO warrants careful consideration because of ECMO's high pre-and post-transplant mortality, most specifically infants <1 year of age, a diagnosis of congenital heart disease, and patients with renal insufficiency.
Single-center reports of waitlist mortality from ECMO range from 29% to 61% in small cohorts of patients. 4, 9, 16, 17 Almond et al 18 recently reported on a merged cohort from both the Organ Procurement and Transplant Network and the Extracorporeal Life Support Organization who were bridged to transplantation from ECMO support with overall waitlist mortality in this cohort of 28%, similar to the 35% at 6 months found in this analysis. However, infants fared much worse in the current analysis with a waitlist mortality of >50% at 3 months. We did not see an association between duration of time on ECMO before listing and waitlist mortality, perhaps being related to this being the most recent cohort of patients after 2005 and the lack of data available before this time. Diagnosis of congenital heart disease in and of itself, as has been reported elsewhere, was associated with the highest waitlist mortality. 5, 11, 18 Unfortunately, listed patients on ECMO support were more likely to be younger and have a diagnosis of congenital heart disease (Table 1) , pointing already to the problem of accumulation of multiple risk factors in these complex patients.
As has been recognized by others, survival post transplant from ECMO support is also clearly suboptimal compared with other transplant recipients. Survival to hospital discharge post-transplant in single-center reports ranges from 66% to 100%, 4, 8, 9, 16, 17, 19 with 1-year survival ranging from 67% to 83% and 5 year survival from 44% to 54%. [7] [8] [9] 13, 19 Despite these overall poorer outcomes reported using ECMO, there are subpopulations of patients on ECMO who clearly are at higher risk of pre-and post-transplant mortality. Identification of risk factors associated with a poor outcome on ECMO would be helpful for clinical decision making and for counseling of parents. The key areas of import would be (1) identification of the patient who should not be placed on to ECMO support as a bridge to transplantation because of a prohibitively high postlisting and post-transplantation morbidity and (2) identification of the patient already on ECMO who acquires a risk factor that would make further support and transplantation futile. These 2 points are paramount in the era of significant organ donor shortages, especially in the infant population. Previous reports are predominantly single center and small numbers that make risk factor analysis not feasible. 4, 5, [8] [9] [10] 17, 19 We also need to learn through additional analysis about the effect of converting these high-risk patients to VAD support. Interestingly, age, ischemic time, and time on ECMO support before listing did not affect post-transplant survival in the ECMO cohort; the latter being somewhat surprising given the reported effect on survival of length of time on ECMO post heart transplant 5, 17 and post cardiotomy (albeit in a singlecenter experience). 7 In fact, Almond et al 18 reported that an ECMO run of >14 days predicted nonsurvival in the larger Organ Procurement and Transplant Network cohort. Perhaps this discrepancy can be explained by an era effect with the data extending back for a 15-year time period in the report by Almond et al 18 compared with a more contemporary cohort (2005-2013) from PHTS. In addition, the total time on ECMO was not taken into account in this analysis.
Although a diagnosis of myocarditis boded well for postlisting survival, it was associated with the lowest post-transplant survival from ECMO, which has also been observed in other series, and hypothesized to be related to immune activation in the setting of active myocarditis or recurrent viral infection in the transplanted heart under immunosuppression. 20 The effect of a diagnosis of congenital heart disease on post-ECMO and post-transplant survival varies in singlecenter experiences from not significantly different 8 to survival rates as low as 25%, 5 perhaps related to center experience and volume among other factors. However, in this larger registrybased analysis, those with a diagnosis of congenital heart disease clearly fare poorly. The effect of impaired renal function has also produced conflicting results with some reports of a negative effect 8, 18, 19 and 1 report showing no significant effect. 4 In this study, 1-unit incremental increases in serum creatinine was significantly associated with worse outcome in this larger series and bears strong consideration as a risk factor.
Although not the focus of this analysis, we have noted the important effect that VAD support has had on post-listing and post-transplant survival. This has also been observed in a previous PHTS study and in the registry for the International Society for Heart and Lung Transplantation. 1, 21 Both studies, as well as the present one, have demonstrated that outcomes on VAD are now equivalent to outcomes without VAD support. Further analysis is required to determine whether these excellent results can be recapitulated for pediatric ECMO patients who are converted to VADs in the pretransplant period. In most cases, a VAD can be implanted without previous ECMO support. However, there are certain circumstances ECMO  135  42  42  56  13  88  2  7  68  453  VAD  1  136  14  5  14  6  1  18  3  198  Neither  67  295  3094  44  52  531  3  32  591  4709  Subtotal  203  473  3150  105  79  625  6  57  662  5360  Total  3826  809 725 ECMO indicates extracorporeal membrane oxygenation; and VAD, ventricular assist device.
where initial ECMO stabilization is desired. Adult transplant programs have increasingly been using ECMO stabilization for INTERMACS 1 patients. 22 There may also be certain subsets of patients such as young children with single ventricle, for whom short-term support with ECMO may be more practical than available pulsatile VAD support.
Deceased organ donor availability remains the limiting factor in heart transplantation, more so in pediatrics-especially young infants. Current organ allocation algorithms have been developed to direct hearts to the sickest recipients to mitigate death while waiting. Such a strategy may reduce post-transplant survival as evidenced in this analysis by the 69.3% 1-year survival after transplantation from ECMO support in comparison with 89.7% for those not requiring ECMO support. The concept of net survival benefit from transplantation in adults has been explored by Singh et al 23 in an adult cohort in the United States. The accompanying clinical perspective on children concluded that sicker children on the waiting list benefit more from heart transplantation unless the post-transplant mortality is predicted to be too high. Where does one draw the line? For an individual patient on ECMO, mortality is close to 100% without transplantation, and it is up to the treating medical team to decide whether bridging to transplant is a feasible option. However, knowledge of the risk factors and likelihood of a good outcome should be considered in this decision making. In this evolving era of mechanical support, outcomes must continue to be closely examined to determine the appropriateness of existing allocation algorithms, criteria for candidacy for heart transplantation, and the effect of different technologies as a bridge to transplantation.
Although this reflects a large, multicenter cohort of >400 patients supported with ECMO as a bridge to heart transplantation, when seeking factors that influence survival, the numbers in subgroups are small making robust statistical statements challenging. Individual institutions contributing data to the PHTS may well have different criteria for listing and bridging patients to heart transplantation. The data forms are not all inclusive, which limited the ability to identify potential risk factors. Despite these limitations, the information is valuable in predicting outcomes and counseling families.
Conclusions
Pediatric patients requiring ECMO support before heart transplant generally have poor outcomes. Identifiable subgroups fare worse, whereas those weaned off before transplantation fare better. Serious consideration needs to be given to the candidacy of these patients, especially in light of the evolving and improving results using VAD support as a bridge to transplant. Prioritization of donor hearts to children waitlisted on ECMO warrants careful consideration because of ECMO's high preand post-transplant mortality. Weight at transplant (lower) 1.37 † 0.04 *Represents the increased risk of a 1-unit increase in creatinine. †Represents the increased risk of a 10-kg decrease in weight.
